Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 1,358 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Resolution Clear all
Completed Phase 2 Interventional Results available

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

NCT04321031
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis With Liver Fibrosis
Interventions
Placebo, PF-06865571, PF-05221304
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
184
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Not applicable Interventional

A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success With Itraconazole But Not With Fluconazole

NCT00002341
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Itraconazole
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Not applicable Interventional

Evaluation of a Digital Diabetes Self-Management Education and Support Program

NCT05368454
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Online Diabetes Self-Management Education and Support (DSMES) Program, Standard of Care
Behavioral
Lead sponsor
Omada Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Not applicable Interventional

Feasibility Study for Imaging of Peripheral Tumors With a High-Resolution PET Imaging System

NCT01008930
View directory record Official record
Conditions
Solid Tumors, Cancer
Interventions
HR PEM Scan
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 29, 2026, 5:07 PM EDT
Completed No phase listed Observational Results available

Continued Anticonvulsants After Resolution of Neonatal Seizures: a Patient-centered Comparative Effectiveness Study

NCT02789176
View directory record Official record
Conditions
Neonatal Seizures
Interventions
Surveys, EEG
Other
Lead sponsor
University of Michigan
Other
Eligibility
0 Weeks to 24 Months
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
San Francisco, California • Stanford, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery

NCT00575380
View directory record Official record
Conditions
Bacterial Infections, Eye Infections, Cataract Extraction
Interventions
AzaSite Eye Drops, Vigamox Eye Drops
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
21 Years and older
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
13
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Mission Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2011 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Different Formulations of LY3074828 in Healthy Participants

NCT03188510
View directory record Official record
Conditions
Healthy
Interventions
LY3074828
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 29, 2026, 5:07 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms

NCT01382810
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Altaire Gel forming solution, Refresh Tears
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Lake Villa, Illinois • Warwick, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 29, 2026, 5:07 PM EDT
Not yet recruiting Not applicable Interventional

EVALUATION OF THE EFFICACY AND TOLERANCE OF VASHE SOLUTION VERSUS SALINE SOLUTION IN THE TREATMENT OF VENOUS OR MIXED LEG ULCERS PRESENTING INFLAMMATORY SIGNS SUGGESTING HEAVY BACTERIAL LOAD

NCT07440797
View directory record Official record
Conditions
Venous Leg Ulcer (VLU)
Interventions
Saline solution, Vashe solution
Device
Lead sponsor
Laboratoires URGO
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 29, 2026, 5:07 PM EDT
Withdrawn Not applicable Interventional

Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma

NCT01489410
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Drug-Eluting Beads (DEB) with Doxorubicin, Lipiodol Ethanol Mixture
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Phase 2 Interventional Results available

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT04742283
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
41
States / cities
Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye

NCT04268069
View directory record Official record
Conditions
Dry Eye Disease
Interventions
PL9643 Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Andover, Massachusetts • Raynham, Massachusetts • Shelby, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

NCT04177082
View directory record Official record
Conditions
Keratoconus, Pellucid Marginal Corneal Degeneration, Corneal Degeneration, Corneal Ectasia
Interventions
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Combination Product
Lead sponsor
Cornea Associates of Texas
Other
Eligibility
8 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 29, 2026, 5:07 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Validation of HyperDetector for SARS-CoV-2

NCT05124496
View directory record Official record
Conditions
SARS-COV2 Infection
Interventions
Screening Device
Device
Lead sponsor
HyperSpectral APD
Industry
Eligibility
5 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 29, 2026, 5:07 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Experimental Peri-implant Mucositis on Implant Sites That Were Previously Treated With or Without Implantoplasty

NCT06063876
View directory record Official record
Conditions
Peri-implant Mucositis, Peri-Implantitis
Interventions
Induction of experimental peri-implant mucositis, Resolution of experimental peri-implant mucositis
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Phase 2 Interventional Results available

Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution

NCT02754596
View directory record Official record
Conditions
Glaucoma Open-angle
Interventions
Travoprost Intraocular Implant, high elution, Travoprost Intraocular Implant, low elution, Timolol Maleate Ophthalmic Solution, 0.5%
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 29, 2026, 5:07 PM EDT
Terminated Not applicable Interventional Results available

Amino Acid-based Oral Rehydration Solution in Children With Short Bowel Syndrome

NCT03105362
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Enterade® oral rehydration solution
Dietary Supplement
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Year to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Not applicable Interventional

Comparison of OPTI-FREE RepleniSH and ReNu Multi-Plus Lens Care Regimens on Corneal Epithelium

NCT00724269
View directory record Official record
Conditions
Contact Lens Wear
Interventions
OPTI-FREE RepleniSH, ReNu MultiPlus MPS
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 29, 2026, 5:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

MRI Study of Tic Remission in Tourette Syndrome

NCT01405859
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Evaluation of 3 Contact Lens Materials With 3 Solution Types

NCT03466060
View directory record Official record
Conditions
Visual Acuity, Slit Lamp Biomicroscopy (Corneal Staining Assessment)
Interventions
Opti-Free : RevitaLens / Clear Care : RevitaLens, Opti-Free : RevitaLens / RevitaLens : Clear Care, Clear Care : RevitaLens/ Opti-Free : RevitaLens, Clear Care : RevitaLens / RevitaLens : Opti-Free, RevitaLens : Clear Care/ Opti-Free : RevitaLens, RevitaLens : Clear Care / RevitaLens : Opti-Free, RevitaLens : Opti-Free / Clear Care : RevitaLens, RevitaLens : Opit-Free / RevitaLens : Clear Care
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
5
States / cities
Anaheim, California • Berkeley, California • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 29, 2026, 5:07 PM EDT
Not yet recruiting Phase 4 Interventional

Effect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal Pain

NCT07849803
View directory record Official record
Conditions
Ocular Pain, Dry Eye
Interventions
acoltremon ophthalmic solution 0.003%
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Phase 3 Interventional

Intranasal Civamide for Episodic Cluster Headache

NCT00069082
View directory record Official record
Conditions
Episodic Cluster Headache
Interventions
Civamide (Zucapsaicin), Sodium Chloride
Drug
Lead sponsor
Winston Laboratories
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
6
States / cities
San Francisco, California • Santa Monica, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 29, 2026, 5:07 PM EDT
Not listed Phase 1Phase 2 Interventional

CelAgace™ OraRinse Solution for Treatment of Candidiasis

NCT03250923
View directory record Official record
Conditions
Candidiasis, Oral
Interventions
silver citrate complex and acemannan
Drug
Lead sponsor
CelaCare Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 29, 2026, 5:07 PM EDT
Recruiting Phase 3 Interventional

OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity

NCT07140783
View directory record Official record
Conditions
Vision Loss Night, Vision Disorders
Interventions
0.75% Phentolamine Ophthalmic Solution, Placebo
Drug
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 29, 2026, 5:07 PM EDT